Underwood, M. (Martin) M.D.. (2008) Gout. Clinical Evidence . ISSN 1752-8526
WRAP_Underwood_Gout.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Official URL: http://clinicalevidence.bmj.com/ceweb/conditions/m...
INTRODUCTION: Gout affects about 5% of men and 1% of women, with up to 80% of people experiencing a recurrent attack within 3 years. METHODS AND OUTCOMES:We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for acute gout? What are the effects of treatments to prevent gout in people with prior acute episodes? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2008 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 21 systematic reviews, RCTs, or observational studies that met our inclusion criteria.We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: colchicine, corticosteroids, corticotrophin (ACTH), non-steroidal anti-inflammatory drugs (NSAIDs), sulfinpyrazone, xanthine oxidase inhibitors, advice to lose weight, advice to reduce alcohol intake, advice to reduce dietary intake of purines.
|Item Type:||Journal Article|
|Subjects:||R Medicine > RC Internal medicine|
|Divisions:||Faculty of Medicine > Warwick Medical School|
|Library of Congress Subject Headings (LCSH):||Gout -- Treatment|
|Journal or Publication Title:||Clinical Evidence|
|Date:||17 November 2008|
|Access rights to Published version:||Open Access|
|References:||1. Emmerson BT. The management of gout. N Engl J Med 1996;334:445–451.[PubMed] 2. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895–900.[PubMed] 3. Kim KY, Schumacher HR, Hunsche E, et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003;25:1593–1616.[PubMed] 4. Harris CM, Lloyd DC, Lewis J.The prevalence and prophylaxis of gout in England. J Clin Epidemiol 1995;48:1153–1158.[PubMed] 5. Abbott RD, Brand FN, Kannel WB, et al. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 1988;41:237–242. [PubMed] 6. Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004;350:1093–1103.[PubMed] 7. Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004;50:2400–2414.[PubMed] 8. Hochberg MC, Thomas J, Thomas DJ, et al. Racial differences in the incidence of gout. The role of hypertension. Arthritis Rheum 1995;38:628–632.[PubMed] 9. Klemp P, Stansfield SA, Castle B, et al. Gout is on the increase in New Zealand. Ann Rheum Dis 1997;56:22–26.[PubMed] 10. McGill NW. Gout and other crystal-associated arthropathies. Baillieres Best Pract Res Clin Rheumatol 2000;14:445–460.[PubMed] 11. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000;27:1501–1505.[PubMed] 12. Schlesinger N, Baker DG, Schumacher HR Jr. Serum urate during bouts of acute gouty arthritis. J Rheumatol 1997;24:2265–2266.[PubMed] 13. Logan JA, Morrison E, McGill PE. Serum uric acid in acute gout. Ann Rheum Dis 1997;56:696–697. 14. Stewart OJ, Silman AJ. Review of UK data on the rheumatic diseases –4. Gout. Br J Rheumatol 1990;29:485–488.[PubMed] 15. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987;82:421–426.[PubMed] 16. Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004;363:1277–1281.[PubMed] 17. Culleton BF. Uric acid and cardiovascular disease: a renal-cardiac relationship? Curr Opin Nephrol Hypertens 2001;10:371–375.[PubMed] 18. Bryan E. Are gout and increased uric acid levels risk factors for cardiac disease? Centre for Clinical Effectiveness, Monash University. 2002. Available online at: http://www.mihsr.monash.org/cce/res/pdf/b/805.pdf (last accessed 7 November 2008). 19. Choi HK, Curhan G, Choi HyonK, et al. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 2008;336:309–312. 20. Bellamy N, Downie WW, Buchanan WW. Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs. Br J Clin Pharmacol 1987;24:33–36.[PubMed] 21. Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout. Ann Intern Med 1961;55:179–192.[PubMed] 22. Gelber AC, Klag MJ, Mead LA, et al. Gout and risk for subsequent coronary heart disease. The Meharry-Hopkins Study. Arch Intern Med 1997;157:1436–1440.[PubMed] 23. Schlesinger N, Schumacher R, Catton M, et al. Colchicine for acute gout. In:The Cochrane Library, Issue 2, 2008. Chichester, UK: John Wiley & Sons, Ltd. Search date 2006.[PubMed] 24. Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987;17:301–304.[PubMed] 25. Schlesinger N, Schumacher HR Jr. Gout: can management be improved? Curr Opin Rheumatol 2001;13:240–244.[PubMed] 26. Underwood M. Diagnosis and management of gout. BMJ 2006;332:1315–1319.[PubMed] 27. Janssens HJ, Lucassen PL, Van de Laar FA, et al. Systemic corticosteroids for acute gout. In: The Cochrane Library, Issue 2, 2008. Chichester, UK: John Wiley & Sons, Ltd. Search date 2007.[PubMed] 28. Man CY, Cheung IT, Cameron PA, et al. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007;49:670–677.[PubMed] 29. Taylor CT, Brookes NC, Kelley KW. Corticotropin for acute management of gout. Ann Pharmacother 2001:35:365–368.[PubMed] 30. Sutaria, S, Katbamna, R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout: a systematic review. Rheumatology 2006;45:1422–1431. Search date 2005; primary sources Medline, Pubmed, Cochrane Controlled Trials Register, ISI Web of Science, Embase, Amed, and hand searches of identified trials and reviews.[PubMed] 31. Garcia de la Torre I. Double-blind parallel study comparing tenoxicam and placebo in acute gouty arthritis. Invet Med Int 1987;14:92–97. [In Spanish] 32. Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004;50:598–606.[PubMed] 33. Schumacher HR Jr, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002;324:1488–1492.[PubMed] 34. Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac ("Lodine") compared with naproxen in patients with acute gout. Curr Med Res Opin 1991;12:423–429.[PubMed] 35. Lederman R. A double-blind comparison of etodolac (Lodine) and high doses of naproxen in the treatment of acute gout. Adv Ther 1990;7:344–354. 36. Altman RD, Honig S, Levin JM, et al. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988;15:1422–1426.[PubMed] 37. Lomen PL, Turner LF, Lamborn KR, et al. Flurbiprofen in the treatment of acute gout. A comparison with indomethacin. Am J Med 1986;80:134–139.[PubMed] 38. Fraser RC, Davis RH, Walker FS. Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia. J R Coll Gen Pract 1987;37:409–411.[PubMed] 39. Non-steroidal anti-inflammatory drugs. In: Royal Pharmaceutical Society of Great Britain, eds. British National Formulary.Wallingford: Pharmaceutical Press, 2008:543–552. 40. Cheng TT, Lai HM, Chiu CK, et al. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clin Ther 2004;26:399–406.[PubMed] 41. Willburger RE, Mysler E, Derbot J, et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology 2007;46:1126–1132.[PubMed] 42. Anon. Gout in primary care. Drug Ther Bull 2004;42:37–40.[PubMed] 43. National Institute for Clinical Excellence. Osteoarthritis.The care and management of osteoarthritis in adults. NICE Clinical Guideline CG 59. 2008. Available at http://www.nice.org.uk/CG59 (last accessed 7 November 2008). 44. Becker MA, Schumacher, HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450–2461.[PubMed] 45. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429–244.[PubMed] 46. Gibson T, Rodgers V, Potter C, et al. Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis 1982;41:59–65.[PubMed]|
Actions (login required)